[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638922":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":25,"centralContacts":30,"locations":41,"responsibleParty":60,"collaborators":10,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":82,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"British Columbia Cancer Agency","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"PET\u002FCT Diagnostic Imaging",null,"Each subject will have two PET\u002FCT scans, one using 68Ga-DOTATATE and the other using 18F-AmBF3-TATE. The 18F-AmBF3-TATE radioactive tracer is manufactured for this study under a Clinical Trial Application filed with Health Canada. 68Ga-DOTATATE is considered standard care and has been approved by Health Canada.",[13,14],"Diagnostic Test: 68Ga-DOTATATE PET\u002FCT","Diagnostic Test: 18F-AmBF3-TATE PET\u002FCT",[16,21],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-DOTATATE PET\u002FCT","Each study participant will have an intravenous catheter inserted. The participant will receive a bolus intravenous dose of the standard of care tracer 68Ga-DOTATATE from an approved study supplier site. The participant will rest in a comfortable chair for 60 minutes. After this uptake phase, the participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Participants are positioned supine, arms down, and centered on the scanner bed and the PET\u002FCT images will be acquired.",[9],{"type":17,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"18F-AmBF3-TATE PET\u002FCT","Each study participant will have an intravenous catheter inserted. The participant will receive a bolus intravenous dose of the investigational tracer 18F-AmBF3-TATE from an approved study supplier site. The participant will rest in a comfortable chair for 60 minutes. After this uptake phase, the participant will then be taken to a designated washroom and asked to void prior to being scanned in order to clear excreted radiotracer activity from the urinary tract. Participants are positioned supine, arms down, and centered on the scanner bed and the PET\u002FCT images will be acquired.",[9],[26],{"name":27,"affiliation":28,"role":29},"Ian Alberts, MBBS MD PhD FEBNM","BC Cancer","PRINCIPAL_INVESTIGATOR",[31,37],{"name":32,"role":33,"phone":34,"phoneExt":35,"email":36},"Research Project Manager","CONTACT","604-675-8000","7649","MITclinicaltrials@bccancer.bc.ca",{"name":38,"role":33,"phone":39,"phoneExt":40,"email":36},"Administrative Research Manager","604-877-6000","2818",[42],{"facility":43,"status":10,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"BC Cancer Vancouver","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":50,"coordinates":51},"Point",[52,53],-123.11934,49.24966,{"lat":53,"lon":52},[56],{"name":57,"role":33,"phone":58,"phoneExt":40,"email":59},"Pavithraa Ravi","6048776000","pavithraa.ravi@bccancer.bc.ca",{"type":61,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100638922","a-comparison-of-68gadotatate-and-18fambf3tate-for-the-staging-and-assessment-of-neuroendocrine-malignancies-100638922",false,"NCT07621146","A Comparison of [68Ga]DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies","A Prospective and Head-to-head Comparison of [68Ga] Ga-DOTATATE and [18F]AmBF3TATE for the Staging and Assessment of Neuroendocrine Malignancies: NET-COMPARE Study","NET-COMPARE","Inclusion Criteria:\n\n* Age ≥18 years\n* Patients referred for and meeting institutional criteria for a \\[68Ga\\]DOTATATE PET\u002FCT for the investigation of a known or suspected neuroendocrine malignancy (BC Cancer criteria APPENDIX A).\n\nExclusion Criteria:\n\n* Pregnant and breast-feeding patients.\n* Patients unwilling or unable to undergo a second PET\u002FCT.\n* Patients exceeding the safe weight limit of the scanner (204.5 kg) or who cannot fit through the PET\u002FCT bore (70cm diameter).","ALL","18 Years",{"count":73,"type":74},51,"ESTIMATED","OBSERVATIONAL","Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of molecules called somatostatin receptors (SSTR) which requires specific PET scan tracers to sufficiently capture on images. The current standard of care tracer at BC Cancer for SSTRs on NETs is 68Ga-DOTATATE. This project seeks to identify if 18F-AmBF3-TATE (a tracer that has established safety from phase 1 trial results), is comparable in disease detection, no. of lesions identified, image quality, safety and overall accuracy, to 68Ga-DOTATATE.",[78,79,80,81],"Neuroendocrine Tumors, NET","Pheochromocytoma\u002FParaganglioma","SSTR-expressing Tumors","Medullary Thyroid Carcinoma","NOT_YET_RECRUITING","2026-05-27",{"date":85,"type":86},"2026-06-02","ACTUAL",{"date":88,"type":74},"2026-09-15",{"date":90,"type":74},"2028-03",{"name":5,"class":6},1]